Twin Tree Management
NBIX icon

Twin Tree Management’s Neurocrine Biosciences NBIX Stock Holding History

Twin Tree Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.28M Buy
17,300
+17,200
+17,200% +$2.28M 0.05% 429
2025
Q4 		$14.2K Sell
100
-7,800
-99% -$1.13M ﹤0.01% 1327
2025
Q3 		$1.11M Sell
7,900
-63,400
-89% -$8.59M ﹤0.01% 1168
2025
Q2 		$8.96M Buy
71,300
+50,900
+250% +$5.84M 0.02% 809
2025
Q1 		$2.26M Sell
20,400
-3,300
-14% -$418K ﹤0.01% 1116
2024
Q4 		$3.24M Buy
23,700
+2,600
+12% +$322K 0.01% 1047
2024
Q3 		$2.43M Buy
+21,100
New +$2.89M ﹤0.01% 1091
2021
Q2 		– Sell
-1,100
Closed -$107K – 1533
2021
Q1 		$107K Buy
+1,100
New +$115K ﹤0.01% 1173
2019
Q4 		– Sell
-13,400
Closed -$1.21M – 1396
2019
Q3 		$1.21M Sell
13,400
-1,600
-11% -$149K ﹤0.01% 795
2019
Q2 		$1.27M Buy
15,000
+13,400
+838% +$1.1M 0.01% 749
2019
Q1 		$141K Buy
+1,600
New +$134K ﹤0.01% 1066
2018
Q4 		– Sell
-8,900
Closed -$1.09M – 1460
2018
Q3 		$1.09M Hold
8,900
– – 0.01% 700
2018
Q2 		$874K Buy
+8,900
New +$797K 0.01% 805

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Twin Tree Management's NBIX Position: Q1 2026 in Review

Twin Tree Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 6,341 shares — an estimated $841K sold.

Twin Tree Management first reported a position in NBIX in Q4 2018 and held it in 22 quarters. The position peaked at $4.86M in Q4 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Twin Tree Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Twin Tree Management sold 6,341 Neurocrine Biosciences shares in Q1 2026, an estimated $841K.
  • Twin Tree Management first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 22 quarters.
  • Twin Tree Management's Neurocrine Biosciences position peaked at $4.86M in Q4 2023.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Twin Tree Management's 13F filing for Q1 2026, filed 14 May 2026.